Orbimed Advisors
$5.2B 13F equity value
136 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Orbimed Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| EWTX | EDGEWISE THERAPEUTICS INC | 15,518,492 | $631M | 12.0% |
| ELVN | ENLIVEN THERAPEUTICS INC | 6,776,632 | $344M | 6.6% |
| LLY | ELI LILLY & CO | 257,900 | $309M | 5.9% |
| MBX | MBX BIOSCIENCES INC | 3,428,736 | $189M | 3.6% |
| SVA | SINOVAC BIOTECH LTD | 2,718,735 | $184M | 3.5% |
| AZN | ASTRAZENECA PLC | 915,700 | $171M | 3.3% |
| GPCR | STRUCTURE THERAPEUTICS INC | 2,209,400 | $119M | 2.3% |
| SION | SIONNA THERAPEUTICS INC | 2,555,877 | $112M | 2.1% |
| CRVS | CORVUS PHARMACEUTICALS INC | 7,165,006 | $107M | 2.0% |
| AVBP | ARRIVENT BIOPHARMA INC | 3,027,328 | $105M | 2.0% |
Track Orbimed Advisors's 13F portfolio: $5.2B in reported holdings, 136 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}